Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2025 Q3 | Oct 21, 2025 | Deep Sail Capital Partners | 5.8% | 18.1% | CLPT, NURS CN, PNG CN | AI, defense, Robotics, small caps, Telehealth | Deep Sail gained 5.8% as positions in Kraken Robotics and Clearpoint Neuro drove performance amid a speculative small-cap environment. The manager sees a bubble forming in speculative assets but remains focused on real growth in defense tech and telehealth innovation like Hydreight. The fund maintains discipline as valuations stretch across markets. | View | |
| 2025 Q3 | Oct 19, 2025 | Minot Light Capital Partners | 7.6% | 12.5% | ARQ, CLPT, CURV, LGCY, LUCD, REAL, SWAG | Biotech, Consumer Stocks, Growth Investing, Life Sciences, small caps | The fund gained modestly but lagged benchmarks as healthcare holdings weighed on results. Managers spotlight RealReals AI-enabled resale growth and industrial cleaner Arqs carbon business while acknowledging short-term weakness in Lucid Diagnostics and Torrid. They maintain conviction in overlooked microcaps with recurring revenue and scalable platforms. | SWAG LUCD CURV ARQ CLPT REAL |
View |
| 2025 Q4 | Jan 18, 2026 | Minot Light Capital Partners | 0.0% | 14.4% | ARQ, CBLL, CLPT, CURV, KRMD, LAKE, LUCD, MAMA, MRVI, NEOG, OM, OWLT, REAL, RXST, RZLT, SWAG, XOMA | Biotech, growth, momentum, Process, small caps, value, volatility | The managers describe unprecedented speed and magnitude of volatility in small/micro-cap space, calling some institutional liquidations violent. They embrace this volatility as it creates opportunities to buy below fair value and sell above fair value, while improving their process to capitalize on these dynamics. The letter discusses how momentum has become an over-owned factor, with many investors avoiding declining stocks. The managers believe taking the other side of downward momentum can be extremely profitable if positioned to ride through volatility, as much trading is now quantitative rather than fundamental. The fund focuses exclusively on small and micro-cap opportunities, believing there is compelling opportunity for meaningful long-term capital appreciation. They discuss how small-caps falling into micro-cap territory face institutional selling pressure when they drop below arbitrary thresholds like $100M market cap. | OM ARQ RZLT XOMA |
View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | Substack | Jam Invest | ClearPoint Neuro, Inc. | Healthcare | Medical Devices | Bull | NASDAQ Stock Market | AMT-130, ClearPoint Neuro, FDA approval, healthcare innovation, investment opportunity, medical technology, Medtech, neurological therapies, regulatory uncertainty, UniQure | View Pitch |
| Feb 4, 2026 | Twitter / X | @mike98572986 | ClearPoint Neuro, Inc. | Health Care | Health Care Equipment | Bull | Nasdaq | AAV, Canada, Crowdfunding, Cytokines, Genetherapy, Glioma, Immunotherapy, IND, Oncology, OrphanDrug | View Pitch |
| Jan 23, 2026 | Twitter / X | @mike98572986 | ClearPoint Neuro, Inc. | Health Care | Health Care Equipment | Bull | NASDAQ | Askbio, Designation, Diseases, Japan, Product Designation, Review, Therapies, You Break | View Pitch |
| Jan 22, 2026 | Twitter / X | @LogicalThesis | ClearPoint Neuro, Inc. | Health Care | Health Care Equipment | Bull | NASDAQ | Binary Risk, Bio, Biotech, Clearpoint, Clinical, Clinical Bio, FDA, rare disease | View Pitch |
| Nov 29, 2025 | Fund Letters | Eddie Reilly | ClearPoint Neuro, Inc. | Health Care | Health Care Equipment & Supplies | Bull | NASDAQ | Cell and gene therapy, Disposables, Installed base, Neurosurgery, pipeline, Reimbursement, switching costs | View Pitch |
| Oct 5, 2025 | Substack | Jam Invest | ClearPoint Neuro | Healthcare | Medical Devices | Bull | capital raising, ClearPoint Neuro, growth potential, Huntington's therapy, Market expansion, Medical devices, minimally invasive surgery, neurology procedures, Parkinson's disease, robotic navigation | View Pitch | |
| Sep 26, 2025 | Seeking Alpha | Seeking Alpha | ClearPoint Neuro, Inc. | Medical Devices | Bull | AMT-130, ClearPoint Neuro, CNS applications, drug delivery, gene therapy, Huntington's Disease, Medical devices, MRI guidance, stock rally, uniQure partnership | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||